Disc Medicine Rare Disease Drug Picked for Faster Regulatory Review Is Rejected by the FDA / MedCity

Frank Vinluan / medcitynews - The FDA asked for more data to determine whether Disc Medicine’s bitopertin is benefiting patients with erythropoietic protoporphyria, a rare blood disorder. Analysts say it’s a surprising delay considering bitopertin is one of the first drugs in a new FD…

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda

---

Saturday, February 21, 2026, 6:22 am / permalink 19516 / 5 stories in 23 days

Related Stories

---

• FDA lifts holds on Intellia’s Phase 3 gene-editing trials / 9 days
• Axpaxli outperforms Eylea in Phase 3; FDA filing expected / 26 days
• BridgeBio’s dwarfism drug posts positive Phase 3 data, FDA filing on track / 4 wks
• FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval / 5 wks
• FDA Accepts Summit Therapeutics' Ivonescimab BLA for EGFR‑Mutant NSCLC / 6 wks
• FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 6 wks
• FDA rejects Corcept’s cortisol modulator triggering setback / 2 months

Related Tags

---

StackHealth Time Machine

---